Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study).
Dung T LeVincent J PicozziAndrew H KoZev A WainbergHedy KindlerAndrea Wang-GillamPaul E ObersteinMichael A MorseHerbert J ZehColin WeekesTony ReidErkut Hasan BorazanciTodd CrocenziNoelle K LoConteBenjamin L MusherDan LaheruAimee MurphyChan WhitingNitya NairAmanda EnstromSandy FerberDirk G BrockstedtElizabeth M JaffeePublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
The combination of Cy/GVAX + CRS-207 did not improve survival over chemotherapy. (ClinicalTrials.gov ID: NCT02004262)See related commentary by Salas-Benito et al., p. 5435.